Today’s guest is Samantha Tabone.  Sam is a Partner at Focalpoint where she leads in-depth technical and scientific due diligence on Empath’s psychedelic biotech investments.  Sam is here to help break down the due diligence process Empath uses when evaluating potential investments in psychedelic biotech companies.  Empath's Due Diligence process is broken down into 4 pillars:  Team, Intellectual Property, Scientific Foundations and Operations / Strategy.  

Prior to Focalpoint, Sam served as the VP of R&D for PurMinds, a neuromedicine startup developing novel therapeutics for neurodegenerative diseases.  As an independent consultant she’s led projects for leading psychedelic companies including Beckley Psytech, advised family offices on Life Science investment strategies, and worked as a temporary strategic director at several biotech startups.  Sam has been fascinated with neuroscience and psychedelics (especially DMT) since she was in her teens.  She’s most excited about funding psychedelic startups working towards solutions for complex neurological disorders.  She holds a B.S. in Chemistry from the University of Toronto and attended the University of Wisconsin-Madison’s Pharmaceutical Sciences Master’s program.